Unlock the Synergy of a 340B Program + Self-Funded Insurance

Anthony Velasquez will clarify the intent of 340B and…

Presented By:

Dave Valentine
PBM Chief Operating Officer

Anthony Velasquez
Chief Product Officer

© 2024 PharmaForce. All rights reserved.

It’s no secret: 340B should work for all eligible patients—even those who might be employees of yours. But all too often, the complexities of PBMs—namely, their lack of flexibility, simplicity, and transparency—make it feel like 340B and Self-Funded Insurance are worlds apart. But they don’t need to be.

Join us for this educational webinar and learn how you can effectively join your employee pharmacy benefits and 340B program to work hand-in-hand, using employee data and insights to improve self-insured plans for employers—and your employees. The result: Greater ease, increased savings, lower drug costs, and better patient care.

Best in KLAS^®. Three years and counting.

We’re proud to report that compared to the four largest TPAs in 340B, PharmaForce emerged as the overall best 340B Third Party Administrator with “A” ratings in every category, including overall performance, Culture, Loyalty, Operations, Product, Relationship, and Value—scoring a 91/100.

Who Should Attend:

Dave Valentine will ask employers to consider their PBMs and…

How entities stretch resources to serve more patients and provide more services

What the major problems facing the 340B programs in healthcare entities are

How PBM and 340B Programs can align to unlock greater savings

• Covered entities in the 340B program
• Finance Directors
• Program Managers
• Pharmacy Directors
• HR Managers/Directors
• Anyone interested in learning more about the 340B program 
  

Anthony Velasquez has over a decade of experience and expertise in the 340B Program 

Dave Valentine has more than 20 years experience and is an industry subject matter expert on PBMs.

1.

2.

3.

1.

2.

3.

What their PBM is doing to drive to the lowest net cost for their self-insured plans

How—or if—their PBM mandates or encourages the use of generic drugs

Why the most clinically effective and lowest cost drugs often aren’t approved